Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation
- PMID: 18430739
- PMCID: PMC2427338
- DOI: 10.1074/jbc.M800224200
Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation
Abstract
Overexpression of enhancer of zeste homologue 2 (EZH2) occurs in various malignancies and is associated with a poor prognosis, especially because of increased cancer cell proliferation. In this study we found an inverse correlation between EZH2 and RUNX3 gene expression in five cancer cell lines, i.e. gastric, breast, prostate, colon, and pancreatic cancer cell lines. Chromatin immunoprecipitation assay showed an association between EZH2 bound to the RUNX3 gene promoter, and trimethylated histone H3 at lysine 27, and HDAC1 (histone deacetylase 1) bound to the RUNX3 gene promoter in cancer cells. RNA interference-mediated knockdown of EZH2 resulted in a decrease in H3K27 trimethylation and unbound HDAC1 and an increase in expression of the RUNX3 gene. Restoration of RUNX3 expression was not associated with any change in DNA methylation status in the RUNX3 promoter region. RUNX3 was repressed by histone deacetylation and hypermethylation of a CpG island in the promoter region and restored by trichostatin A or/and 5-aza-2'-deoxycytidine. Immunofluorescence staining confirmed restoration of expression of the RUNX3 protein after knockdown of EZH2 and its restoration resulted in decreased cell proliferation. In vivo, an inverse relationship between expression of the EZH2 and RUNX3 proteins was observed at the individual cell level in gastric cancer patients in the absence of DNA methylation in the RUNX3 promoter region. The results showed that RUNX3 is a _target for repression by EZH2 and indicated an underlying mechanism of the functional role of EZH2 overexpression on cancer cell proliferation.
Figures
Similar articles
-
The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer.Carcinogenesis. 2010 Sep;31(9):1567-75. doi: 10.1093/carcin/bgq147. Epub 2010 Jul 14. Carcinogenesis. 2010. PMID: 20631058 Free PMC article.
-
Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.Cancer Sci. 2008 Apr;99(4):738-46. doi: 10.1111/j.1349-7006.2008.00743.x. Cancer Sci. 2008. PMID: 18377425 Free PMC article.
-
Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.J Biol Chem. 2005 Jun 10;280(23):22437-44. doi: 10.1074/jbc.M501379200. Epub 2005 Apr 6. J Biol Chem. 2005. PMID: 15817459
-
EZH2 methyltransferase and H3K27 methylation in breast cancer.Int J Biol Sci. 2012;8(1):59-65. doi: 10.7150/ijbs.8.59. Epub 2011 Nov 18. Int J Biol Sci. 2012. PMID: 22211105 Free PMC article. Review.
-
Aberrations of EZH2 in cancer.Clin Cancer Res. 2011 May 1;17(9):2613-8. doi: 10.1158/1078-0432.CCR-10-2156. Epub 2011 Mar 2. Clin Cancer Res. 2011. PMID: 21367748 Review.
Cited by
-
Knockdown of RNF2 induces apoptosis by regulating MDM2 and p53 stability.Oncogene. 2014 Jan 23;33(4):421-8. doi: 10.1038/onc.2012.605. Epub 2013 Jan 14. Oncogene. 2014. PMID: 23318437 Free PMC article.
-
SUMOylation of E2F1 Regulates Expression of EZH2.Cancer Res. 2020 Oct 1;80(19):4212-4223. doi: 10.1158/0008-5472.CAN-20-1259. Epub 2020 Aug 14. Cancer Res. 2020. PMID: 32816857 Free PMC article.
-
EZH2 Mediates Proliferation, Migration, and Invasion Promoted by Estradiol in Human Glioblastoma Cells.Front Endocrinol (Lausanne). 2022 Feb 7;13:703733. doi: 10.3389/fendo.2022.703733. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35197928 Free PMC article.
-
Treatment of breast cancer cells with DNA demethylating agents leads to a release of Pol II stalling at genes with DNA-hypermethylated regions upstream of TSS.Nucleic Acids Res. 2011 Dec;39(22):9508-20. doi: 10.1093/nar/gkr611. Epub 2011 Aug 31. Nucleic Acids Res. 2011. PMID: 21880597 Free PMC article.
-
_targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.Nat Chem Biol. 2013 Oct;9(10):643-50. doi: 10.1038/nchembio.1331. Epub 2013 Aug 25. Nat Chem Biol. 2013. PMID: 23974116 Free PMC article.
References
-
- Ito, Y. (2004) Oncogene 23 4198-4208 - PubMed
-
- Inoue, K., Ozaki, S., Shiga, T., Ito, K., Masuda, T., Okado, N., Iseda, T., Kawaguchi, S., Ogawa, M., Bae, S. C., Yamashita, N., Itohara, S., Kudo, N., and Ito, Y. (2002) Nat. Neurosci. 5 946-954 - PubMed
-
- Taniuchi, I., Osato, M., Egawa, T., Sunshine, M. J., Bae, S. C., Komori, T., Ito, Y., and Littman, D. R. (2002) Cell 111 621-633 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous